Opus Genetics在黄斑学会年会公布Opgx-Best1基因疗法1/2期研究初步临床数据

美股速递
Feb 27

OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展,为后续临床开发提供了关键依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10